A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Tumor vaccine efficacy relies on immunostimulation of antigen-presenting cells (APCs) within the tumor microenvironment.
• Toll-like receptor 3 (TLR3) stimulation, particularly by double-stranded RNA (dsRNA), is crucial for generating effective vaccine-induced cellular immune responses.
• Current Poly I:C-based TLR3 agonists face limitations due to size heterogeneity, stability issues, and toxicity associated with lipid nanoparticle (LNP) delivery systems.

Purpose of the Study:

• To develop an improved nanoparticle system for myeloid cell targeting and immune stimulation.
• To create a novel TLR3 agonist delivery platform with enhanced stability and reduced toxicity compared to existing LNPs.
• To design a myeloid targeting immune enhancer cocktail combining a refined TLR3 agonist with small molecule NF-κB stimulators.

Main Methods:

• Design of a myeloid cell targeting nanoparticle system named MyTai, incorporating a refined TLR3 agonist (NexaVant, NVT) and NF-κB stimulators.
• MyTai nanoparticles were synthesized using ferrocenoyl-aminoguanidine modified cross-linked bis succinyl cyclodextrin, achieving a diameter of approximately 100 nm.
• Systemic administration of MyTai was evaluated for its robustness, stability, efficacy in tumor eradication, and toxicity profile.

Main Results:

• MyTai nanoparticles demonstrated exceptional robustness and stability.
• The system was highly efficacious in eradicating multiple tumor types.
• MyTai exhibited low toxicity upon systemic administration, presenting a safer alternative to LNP-based delivery.

Conclusions:

• MyTai represents a robust, stable, and low-toxicity nanoparticle system for immune stimulation.
• This novel platform effectively targets myeloid cells and enhances anti-tumor immune responses.
• MyTai offers a viable and less toxic alternative to current LNP RNA delivery platforms for cancer immunotherapy.